Published in N Engl J Med on April 15, 1999
Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer (TACO) | NCT01561586
Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients | NCT02309658
Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix (NELCER) | NCT03256916
Validation of the Genetic Signature 354849 as a Prognostic Method | NCT04067882
Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila) (2009) 3.70
Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol (2008) 3.45
Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol (2011) 2.85
Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ (2001) 2.56
Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Group experience from 1990 to 2005. J Clin Oncol (2009) 2.52
Inhibition of transcription by platinum antitumor compounds. Metallomics (2009) 1.88
Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys (2012) 1.77
Substantial improvement in UK cervical cancer survival with chemoradiotherapy: results of a Royal College of Radiologists' audit. Clin Oncol (R Coll Radiol) (2010) 1.76
Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol (2007) 1.70
Synchronous chemoradiation for squamous carcinomas. BMJ (2001) 1.61
Consequences of cisplatin binding on nucleosome structure and dynamics. Chem Biol (2010) 1.51
Feasibility of concurrent cisplatin use during primary and adjuvant chemoradiation therapy: a phase I study in Japanese patients with cancer of the uterine cervix. Int J Clin Oncol (2006) 1.50
Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci U S A (2000) 1.46
Improved treatment for cervical cancer--concurrent chemotherapy and radiotherapy. N Engl J Med (1999) 1.45
Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer. Clin Cancer Res (2010) 1.45
5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs (2000) 1.40
The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. Mol Pharmacol (2008) 1.37
Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br J Cancer (2006) 1.28
KIAA1018/FAN1 nuclease protects cells against genomic instability induced by interstrand cross-linking agents. Proc Natl Acad Sci U S A (2010) 1.25
Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.22
Accelerated publication versus usual publication in 2 leading medical journals. CMAJ (2002) 1.20
Whole pelvic helical tomotherapy for locally advanced cervical cancer: technical implementation of IMRT with helical tomotherapy. Radiat Oncol (2009) 1.12
Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer. Clin Cancer Res (2012) 1.09
Diagnosis and management of cervical cancer. BMJ (2007) 1.09
Radiosensitizers in cervical cancer. Cisplatin and beyond. Radiat Oncol (2006) 1.07
Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer (2000) 1.07
A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. Br J Cancer (2013) 1.00
The microRNA-218~Survivin axis regulates migration, invasion, and lymph node metastasis in cervical cancer. Oncotarget (2015) 1.00
Ultra-early predictive assay for treatment failure using functional magnetic resonance imaging and clinical prognostic parameters in cervical cancer. Cancer (2010) 0.98
A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group study. Gynecol Oncol (2008) 0.97
Phase II study of tri-weekly cisplatin and irinotecan as neoadjuvant chemotherapy for locally advanced cervical cancer. Oncol Lett (2010) 0.97
Survival outcomes of patients with advanced oral cavity squamous cell carcinoma treated with multimodal therapy: a multi-institutional analysis. J Otolaryngol Head Neck Surg (2013) 0.97
Co-expression of CD147 and GLUT-1 indicates radiation resistance and poor prognosis in cervical squamous cell carcinoma. Int J Clin Exp Pathol (2014) 0.97
Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer. Treatment planning, quality control, and clinical implementation. Strahlenther Onkol (2009) 0.96
Pelvic fractures after radiotherapy for cervical cancer: implications for survivors. Cancer (2010) 0.96
Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs (2012) 0.96
Nedaplatin: a radiosensitizing agent for patients with cervical cancer. Chemother Res Pract (2010) 0.95
The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. J Neurooncol (2008) 0.94
Treatment of squamous cell carcinoma of the uterine cervix with radiation therapy alone: long-term survival, late complications, and incidence of second cancers. Br J Cancer (2007) 0.94
A study of high-dose-rate intracavitary brachytherapy boost for curative treatment of uterine cervical cancer. J Contemp Brachytherapy (2015) 0.94
The pretreatment neutrophil-to-lymphocyte ratio predicts therapeutic response to radiation therapy and concurrent chemoradiation therapy in uterine cervical cancer. Int J Clin Oncol (2015) 0.93
Promising treatment results of adjuvant chemotherapy following radical hysterectomy for intermediate risk stage 1B cervical cancer. Obstet Gynecol Sci (2013) 0.93
Global phosphoproteome profiling reveals unanticipated networks responsive to cisplatin treatment of embryonic stem cells. Mol Cell Biol (2011) 0.93
Addition of gemcitabine to standard therapy in locally advanced cervical cancer: A randomized comparative study. Indian J Med Paediatr Oncol (2011) 0.92
Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res (2013) 0.92
Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev (2012) 0.92
Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer. J Gynecol Oncol (2012) 0.90
Patterns of care for women with cervical cancer in the United States. Cancer (2008) 0.90
Patient-derived xenograft models in gynecologic malignancies. Am Soc Clin Oncol Educ Book (2014) 0.90
A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer. Radiat Oncol (2010) 0.90
Prognostic significance of pathological response after neoadjuvant chemotherapy or chemoradiation for locally advanced cervical carcinoma. Int Semin Surg Oncol (2006) 0.89
Definitive radiation therapy for invasive carcinoma of the vagina: impact of high-dose rate intracavitary brachytherapy. Int J Clin Oncol (2012) 0.89
Morbid obesity as an independent risk factor for disease-specific mortality in women with cervical cancer. Obstet Gynecol (2014) 0.89
Impact of concurrent chemotherapy on definitive radiotherapy for women with FIGO IIIb cervical cancer. J Radiat Res (2012) 0.89
A review of topotecan in combination chemotherapy for advanced cervical cancer. Ther Clin Risk Manag (2008) 0.89
Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin. Five-year results. BMC Womens Health (2006) 0.89
Current status and perspectives of brachytherapy for cervical cancer. Int J Clin Oncol (2009) 0.89
Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix. Cancer Chemother Pharmacol (2012) 0.88
Helical tomotherapy in cervical cancer patients: simultaneous integrated boost concept: technique and acute toxicity. Strahlenther Onkol (2010) 0.88
Radiotherapy versus concurrent 5-day cisplatin and radiotherapy in locally advanced cervical carcinoma. Long-term results of a phase III randomized trial. Strahlenther Onkol (2009) 0.87
Aminopeptidase N (APN)/CD13 inhibitor, Ubenimex, enhances radiation sensitivity in human cervical cancer. BMC Cancer (2008) 0.87
Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases. Oncotarget (2015) 0.87
A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study. Gynecol Oncol (2011) 0.87
Adjuvant chemotherapy, a valuable alternative option in selected patients with cervical cancer. PLoS One (2013) 0.87
Differing prognosis of cervical cancer patients with high risk of treatment failure after radical hysterectomy warrants trial treatment modification. J Gynecol Oncol (2009) 0.87
EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy. BMC Cancer (2008) 0.87
Adjuvant hysterectomy for treatment of residual disease in patients with cervical cancer treated with radiation therapy. Br J Cancer (2008) 0.86
Experience in stage IB2 cervical cancer and review of treatment. J Turk Ger Gynecol Assoc (2010) 0.86
Stereotactic body radiotherapy as an alternative to brachytherapy in gynecologic cancer. Biomed Res Int (2013) 0.86
Long-term follow-up of neoadjuvant intraarterial chemotherapy using an original four-lumen double-balloon (4L-DB) catheter for locally advanced uterine cervical cancer. Int J Clin Oncol (2009) 0.86
Concurrent chemoradiation for vaginal cancer. PLoS One (2013) 0.86
Cervical cancer treatment with a locally insertable controlled release delivery system. J Control Release (2006) 0.86
Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma. Drug Des Devel Ther (2015) 0.85
Correlation between tumor volume response to radiotherapy and expression of biological markers in patients with cervical squamous cell carcinoma. J Gynecol Oncol (2009) 0.85
Overall survival after pelvic exenteration for gynecologic malignancy. Gynecol Oncol (2014) 0.85
Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review. Int J Clin Oncol (2008) 0.85
Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 0.85
Expression of mitotic-arrest deficiency 2 predicts the efficacy of neoadjuvant chemotherapy for locally advanced uterine cervical cancer. Exp Ther Med (2011) 0.85
Survival benefits of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy in locally advanced chemoresistant cervical cancer. J Korean Med Sci (2006) 0.85
Pelvic irradiation modulates the pharmacokinetics of cisplatin in the plasma and lymphatic system. Am J Transl Res (2015) 0.85
Progress in gynecologic cancer research: the Gynecologic Oncology Group experience. Semin Oncol (2008) 0.85
A randomized controlled study of single-agent cisplatin and radiotherapy versus docetaxel/cisplatin and radiotherapy in high-risk early-stage cervical cancer after radical surgery. J Cancer Res Clin Oncol (2013) 0.84
Use of serum squamous cell carcinoma antigen for follow-up monitoring of cervical cancer patients who were treated by concurrent chemoradiotherapy. Radiat Oncol (2010) 0.84
Structure-based DNA-targeting strategies with small molecule ligands for drug discovery. Med Res Rev (2013) 0.84
Cisplatin chemotherapy (without erythropoietin) and risk of life-threatening thromboembolic events in carcinoma of the uterine cervix: the tip of the iceberg? A review of the literature. Radiat Oncol (2006) 0.84
Posttreatment cut-off levels of squamous cell carcinoma antigen as a prognostic factor in patients with locally advanced cervical cancer treated with radiotherapy. J Gynecol Oncol (2013) 0.83
Characterization of the Tumor-Microenvironment in Patient-Derived Cervix Xenografts (OCICx). Cancers (Basel) (2012) 0.83
Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: a retrospective analysis in a Japanese cohort. J Gynecol Oncol (2014) 0.83
Definitive extended field intensity-modulated radiotherapy and concurrent cisplatin chemosensitization in the treatment of IB2-IIIB cervical cancer. J Gynecol Oncol (2014) 0.83
Therapeutic Mechanisms of Treatment in Cervical and Vaginal Cancer. Oncol Hematol Rev (2012) 0.83
Incidence of radiation toxicity in cervical cancer and endometrial cancer patients treated with radiotherapy alone versus adjuvant radiotherapy. Rep Pract Oncol Radiother (2012) 0.83
Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer: a long-term follow-up study. J Gynecol Oncol (2013) 0.83
Human Papillomavirus E6/E7-Specific siRNA Potentiates the Effect of Radiotherapy for Cervical Cancer in Vitro and in Vivo. Int J Mol Sci (2015) 0.82
Lymphadenectomy in locally advanced cervical cancer study (LiLACS): Phase III clinical trial comparing surgical with radiologic staging in patients with stages IB2-IVA cervical cancer. J Minim Invasive Gynecol (2013) 0.82
Population-level trends in relative survival for cervical cancer. Am J Obstet Gynecol (2015) 0.82
Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature (2000) 8.59
Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys (1997) 8.58
Genome of the bacterium Streptococcus pneumoniae strain R6. J Bacteriol (2001) 7.97
Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst (1993) 7.87
Assessment of the sensitivity and specificity of oligonucleotide (50mer) microarrays. Nucleic Acids Res (2000) 6.20
Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ (1991) 5.45
Simulation of Sahel drought in the 20th and 21st centuries. Proc Natl Acad Sci U S A (2005) 4.70
Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science (2000) 4.57
Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys (1995) 4.26
PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene. Proc Natl Acad Sci U S A (1993) 4.05
Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13. Int J Radiat Oncol Biol Phys (1995) 3.86
Comparative sequence analysis of a gene-rich cluster at human chromosome 12p13 and its syntenic region in mouse chromosome 6. Genome Res (1998) 3.80
Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol (2003) 3.73
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res (1996) 3.60
The sedative component of anesthesia is mediated by GABA(A) receptors in an endogenous sleep pathway. Nat Neurosci (2002) 3.52
Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys (1995) 3.32
Association of low levels of mannan-binding protein with a common defect of opsonisation. Lancet (1989) 3.12
PATRIC: the VBI PathoSystems Resource Integration Center. Nucleic Acids Res (2006) 3.06
Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med (2000) 2.79
Melanopsin in cells of origin of the retinohypothalamic tract. Nat Neurosci (2001) 2.79
SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother (2006) 2.75
The ARF1 GTPase-activating protein: zinc finger motif and Golgi complex localization. Science (1995) 2.72
Human homologues of yeast helicase. Nature (1996) 2.71
Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer (2007) 2.71
Ovarian carcinomas with transitional cell carcinoma pattern. Am J Clin Pathol (1990) 2.70
Potential biological effects following high X-ray dose interventional procedures. J Vasc Interv Radiol (1994) 2.67
The human fibroblast growth factor receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain. Mol Cell Biol (1991) 2.63
Requirement of the MADS-box transcription factor MEF2C for vascular development. Development (1998) 2.63
The histone acetylase PCAF is a nuclear receptor coactivator. Genes Dev (1998) 2.58
Nitriding iron at lower temperatures. Science (2003) 2.55
A high-density integrated genetic linkage and radiation hybrid map of the laboratory rat. Genome Res (1999) 2.49
MicroRT-small animal conformal irradiator. Med Phys (2007) 2.46
Guanine nucleotide associated with the protein of the outer fibers of flagella and cilia. Science (1967) 2.34
Diverse forms of a receptor for acidic and basic fibroblast growth factors. Mol Cell Biol (1990) 2.33
Deafness and imbalance associated with inactivation of the secretory Na-K-2Cl co-transporter. Nat Genet (1999) 2.20
Recombinant rat CBF-C, the third subunit of CBF/NFY, allows formation of a protein-DNA complex with CBF-A and CBF-B and with yeast HAP2 and HAP3. Proc Natl Acad Sci U S A (1995) 2.17
Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys (2001) 2.14
Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma. DNA Cell Biol (1994) 2.13
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol (2000) 2.12
Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys (1995) 2.08
Atomistic free-volume zones and inelastic deformation of metallic glasses. Nat Mater (2010) 2.08
Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol (2001) 2.05
Simultaneous shotgun sequencing of multiple cDNA clones. DNA Seq (1997) 2.04
Distant metastases after irradiation alone in carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys (1992) 2.03
Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res (1986) 2.01
Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys (1993) 1.99
Evolution and replacement of Candida albicans strains during recurrent vaginitis demonstrated by DNA fingerprinting. J Clin Microbiol (1994) 1.99
Retrograde transport from the yeast Golgi is mediated by two ARF GAP proteins with overlapping function. EMBO J (1999) 1.97
Effect of rest interval on tumor and normal tissue response--a report of phase III study of accelerated split course palliative radiation for advanced pelvic malignancies (RTOG-8502) Int J Radiat Oncol Biol Phys (1993) 1.96
IA-1, a new marker for neuroendocrine differentiation in human lung cancer cell lines. Cancer Res (1993) 1.96
Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol (2000) 1.95
The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut-brain communication. Neurogastroenterol Motil (2011) 1.93
LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest (1998) 1.89
Genetic similarity of Candida albicans strains from vaginitis patients and their partners. J Clin Microbiol (1993) 1.85
Orexin (hypocretin) neurons contain dynorphin. J Neurosci (2001) 1.84
Variations in KCNQ1 are associated with type 2 diabetes and beta cell function in a Chinese population. Diabetologia (2009) 1.83
Paget's disease of the vulva: pathology, pattern of involvement, and prognosis. Gynecol Oncol (2000) 1.82
Requirement of the histone demethylase LSD1 in Snai1-mediated transcriptional repression during epithelial-mesenchymal transition. Oncogene (2010) 1.80
A hierarchy of SSB protomers in replication protein A. Genes Dev (1996) 1.80
Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci (2005) 1.78
Specific interaction of the PDZ domain protein PICK1 with the COOH terminus of protein kinase C-alpha. J Biol Chem (1997) 1.78
Analysis of ten Brucella genomes reveals evidence for horizontal gene transfer despite a preferred intracellular lifestyle. J Bacteriol (2009) 1.76
Electrophoretically uniform fluorescent dyes for automated DNA sequencing. Science (1996) 1.75
Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res (2001) 1.74
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol (2001) 1.73
Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol (2000) 1.71
A gene-rich cluster between the CD4 and triosephosphate isomerase genes at human chromosome 12p13. Genome Res (1996) 1.66
A role for serum response factor in coronary smooth muscle differentiation from proepicardial cells. Development (1999) 1.62
An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-α and cAMP/PKA pathways. Leukemia (2011) 1.61
MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet (1999) 1.61
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Wavelet transform domain filters: a spatially selective noise filtration technique. IEEE Trans Image Process (1994) 1.60
Hypoxia-associated induction of early growth response-1 gene expression. J Biol Chem (1999) 1.60
beta-catenin in epithelial morphogenesis: conversion of part of avian foot scales into feather buds with a mutated beta-catenin. Dev Biol (2000) 1.59
Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol (2001) 1.59
Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia (2009) 1.59
Quantification of intracavitary brachytherapy parameters and correlation with outcome in patients with carcinoma of the cervix. Int J Radiat Oncol Biol Phys (2000) 1.58
De-regulation of GRP stress protein expression in human breast cancer cell lines. Breast Cancer Res Treat (1999) 1.57
"Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis. J Clin Endocrinol Metab (1982) 1.57
Saccharomyces cerevisiae Gcs1 is an ADP-ribosylation factor GTPase-activating protein. Proc Natl Acad Sci U S A (1996) 1.57
Space and time in the nucleus: developmental control of replication timing and chromosome architecture. Cold Spring Harb Symp Quant Biol (2010) 1.57
Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol (1999) 1.56
Chemoprevention of esophageal tumorigenesis by dietary administration of lyophilized black raspberries. Cancer Res (2001) 1.56
Severity of leukoaraiosis correlates with clinical outcome after ischemic stroke. Neurology (2009) 1.56
Primary medical management of recurrent aggressive angiomyxoma of the vulva with a gonadotropin-releasing hormone agonist. Gynecol Oncol (2001) 1.55
Tumor recurrence in stage I ovarian serous neoplasms of low malignant potential. Int J Gynecol Pathol (1998) 1.54
High-dose-rate brachytherapy for carcinoma of the cervix: high tech or high risk? Int J Radiat Oncol Biol Phys (1992) 1.54
Figo IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy. Int J Radiat Oncol Biol Phys (1999) 1.54
Irradiation alone or combined with surgery in stage IB, IIA, and IIB carcinoma of uterine cervix: update of a nonrandomized comparison. Int J Radiat Oncol Biol Phys (1995) 1.54
Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol (1999) 1.53
RTOG's first quality of life study--RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys (1995) 1.52
COPD in Chinese nonsmokers. Eur Respir J (2009) 1.52
Prognostic factors in adult granulosa cell tumor of the ovary. Cancer (1997) 1.49
Bulky endocervical carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys (1992) 1.49